Pay in 4 interest-free payments of $6.02 Learn more
Ships within 48 hours · Estimated delivery Oct 30 - Nov 4
AKI occurred in 57.1% of non-dialysis patients, and severe hypoglycemia was reported in two patients (11.8%)
This evidence-based recommendation reflects the maturity of the research supporting these medications
Desbois-Mouthon C, Baron A, Blivet-Van Eggelpol MJ, Fartoux L, Venot C, Bladt F, et al
doi: 10.2337/db22-727-P 88 ChavdaVPAjabiyaJTeliDBojarskaJApostolopoulosV
Moreover, peptide analogues that are unimolecular co-agonists of both GLP-1R and GCGR are currently in clinical development for the treatment of T2D, obesity and non-alcoholic steatohepatitis (NASH) 2,3,5,6,7
US$ 24.75
US$ 20.25
US$ 23.91
US$ 28.09
US$ 28.77
US$ 25.03
